Pharmaceutical Sciences ETDs

Publication Date

Spring 4-15-2022


Electronic cigarette or vaping use associated lung injury (EVALI) is a pulmonary disease among those who vaped illicit tetrahydrocannabinol (THC) cartridges that resulted in hospitalization or death. Vitamin E acetate (VEA) was a common additive present in the bronchioalveolar lavage fluid (BALF) of patients who were hospitalized with EVALI. However, little is known about pulmonary exposure to vitamin E acetate (VEA) when inhaled through vaping. The hypothesis of this study is the cytotoxicity of vaped VEA is due, at least in part, to the pyrolytic breakdown products of VEA produced by vaping, as opposed to VEA itself. From this study, VEA was not found to exhibit cytotoxicity on THP-1 human monocytic cells; however, vaped VEA showed toxicity. Multiple VEA byproducts, and VEA, were observed by spectrophotometric, HPLC, GCMS, LCMS, and LCMS/MS analysis. A peak with a molecular weight of 390 remained consistent in all vaped VEA collections.

Fourth Committee Member

Dr.Graham Timmins

First Committee Member (Chair)

Dr.Todd Thompson

Degree Name

Pharmaceutical Sciences

Second Committee Member

Dr. Matthew Campen

Level of Degree


Third Committee Member

Dr. Pavan Muttil

Department Name

College of Pharmacy

Document Type